Gilead Sciences reported $30.5B of revenue over the trailing twelve months, +5.5% on the year before. 11 reported series are charted on this page, each one as filed. Revenue, trailing twelve months: $30.5B (to Q2 2026). Net Income: −$3.24B, trailing twelve months to Q2 2026. Free Cash Flow: $12.9B, trailing twelve months to Q2 2026. Op Margin: −7.0%, trailing twelve months to Q2 2026.

GILDGilead Sciences

HealthcareUSD

$148.13

$107.4852 weeks$153.91

GILD as reported

Gilead Sciences reported $30.5B of revenue over the trailing twelve months, +5.5% on the year before. 11 reported series are charted on this page, each one as filed.

$30.5B

Revenue, trailing twelve months · to Q2 2026 · +5.5% against the twelve months before

Net Income: −$3.24B
Net Income · −151% year on year · trailing twelve months to Q2 2026
Free Cash Flow: $12.9B
Free Cash Flow · +38% year on year · trailing twelve months to Q2 2026
Op Margin: −7.0%
Op Margin · trailing twelve months to Q2 2026

Every series Ryufin has for GILD, trailing twelve months
Series	Latest	Year on year	As of
Revenue	$30.5B	+5.5%	Q2 2026
Net Income	−$3.24B	−151%	Q2 2026
EPS	−$2.67	−153%	Q2 2026
Gross Margin	80%	n/a	Q2 2026
Op Margin	−7.0%	n/a	Q2 2026
Net Margin	−9.7%	n/a	Q2 2026
ROE	22%	n/a	Q2 2026
ROA	9.5%	n/a	Q2 2026
ROIC	14%	n/a	Q2 2026
Free Cash Flow	$12.9B	+38%	Q2 2026
P/E	18.8	n/a	Q1 2026